Objective: To investigate the impact of pharmacological interventions on the rationality and gastrointestinal adverse reactions of prophylactic use of proton pump inhibitors (PPIs) in chemotherapy patients, and to provide reference for the rational use of clinical PPIs. Methods: A total of 925 tumor patients, admitted to the Department of Oncology of the Sixth People's Hospital of Nantong from December 2019 to November 2020, without pharmacological intervention were selected as the non-pharmacological intervention group, and 480 tumor patients, admitted to the Department of Oncology of the Sixth People's Hospital of Nantong from December 2020 to November 2021, with pharmacological interventions were selected as the pharmacological intervention group. The prophylactic use of PPIs and the occurrence rate of gastrointestinal adverse reactions caused by PPIs in the two groups were analyzed and compared. Results: The prophylactic use rate of PPIs in the pharmacological intervention group was lower than that in the non-pharmacological intervention group (78.33% vs. 84.76%, P<0.05), but the differences in the occurrence rate of irrational drug use and of the gastrointestinal adverse reactions caused by PPIs between the two groups were not statistically significant (P>0.05). Conclusion: The prophylactic use of PPIs in oncology patients can be reduced with pharmaceutical interventions performed by pharmacists, but the rationality of their prophylactic use and the occurrence of adverse reactions are not greatly affected.
Key words
proton pump inhibitor /
pharmacological intervention /
chemotherapy patient /
gastrointestinal adverse reaction /
prophylactic use
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 郑荣寿,孙可欣,张思维,等. 2015 年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019,41(1):19-28.
[2] Hafeez U, Parakh S, Gan HK, et al. Antibody-drug conjugates for cancer therapy[J]. Molecules, 2020, 25(26): 1-33.
[3] Szabó IL, Mátics R, Hegyi P, et al. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2Ras: a systematic review and meta-analysis[J]. J Gastrointest Liver, 2017, 26(4): 395-402.
[4] 国家卫生健康委员会. 质子泵抑制剂临床应用指导原则(2020版)[J].中国实用乡村医生杂志,2021,28(1): 1-9.
[5] 质子泵抑制剂预防性应用专家共识写作组. 质子泵抑制剂预防性应用专家共识[J].中国医师杂志,2018,20(12): 1775-1781.
[6] 中国药学会医院药学专业委员会. 质子泵抑制剂优化应用专家共识[J].中国医院药学杂志,2020,40(21):2195-2213.
[7] Katz PO, Gerson LB, Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J].Am J Gastroenterol, 2013, 108(3): 308-328.
[8] Esteves M, Rollason V, Grosgurin O.Proton pump inhibitors overprescription[J]. Revue Medicale Suisse, 2017, 13(579):1782-1786.
[9] Hoteit M, Mattar E, Allaw R, et al. Epidemiological study assessing the overuse of proton pump inhibitors in lebanese population[J]. Middle East J Dig Dis, 2020, 12(4): 265-270.
[10] Pasina L, Novella A, Elli C, et al. Overuse of proton pump inhibitors in nursing homes: an Italian multicenter observational study[J]. Pharmacoepidemiology and drug safety, 2020, 29(4):461-466.
[11] Yibirin M, De Oliveira D, Valera R, et al. Adverse effects associated with proton pump inhibitor use[J]. Cureus, 2021,13(1):1-6.
[12] Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients[J]. ESMO Open, 2021, 6(5): 100231.
[13] Lanas-Gimeno A, Hijos G, Lanas Á.Proton pump inhibitors, adverse events and increased risk of mortality[J]. Expert Opin Drug Saf, 2019, 18(11): 1043-1053.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(1657 KB)
